← Back

Zhejiang Shapuaisi Pharmaceutical Co Ltd

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antimicrobials, gynecology, and other classes. It offers its products in injections, oral solutions, eye drops, large-volume injections, oral solutions, tablets, granules, and other dosage forms. It also offers medical and health care, and scientific research and teaching facilities. Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. was founded in 2000 and is based in Pinghu, China.

Price · split & dividend adjusted
News & notes moving 603168.CG
603168.CG▲4

Shapuaisi Obtains Drug Registration Certificate for Vitamin B12 Eye Drops

Shapuaisi announced that the company has received the drug registration certificate for Vitamin B12 Eye Drops issued by the National Medical Products Administration. The specification is 0.02% (5ml:1mg), the registration classification is chemical drug category 4, and it is indicated for relieving symptoms of accommodative asthenopia. The company's cumulative R&D investment for this drug is approximately 4.1913 million yuan.
603168.CG ▲
Jiemian·20dRead more ▾
Biotech & Genomic Medicine▼

Qilu Pharmaceutical's atropine sulfate eye drops application accepted, intensifying competition in children's myopia drug market

Qilu Pharmaceutical's marketing application for atropine sulfate eye drops, filed under chemical drug registration category 2.2, was accepted by the Center for Drug Evaluation of the National Medical Products Administration on July 24. The indication is to slow the progression of myopia in children. Currently, only Xingqi Pharmaceutical's 0.01% atropine sulfate eye drops have been approved for marketing in this field, in March 2024, with nationwide sales reaching 603.6 million yuan in 2025, a year-on-year increase of 212%. Similar products from companies such as Hengrui Medicine's subsidiary Shengdi Pharmaceutical and Zhaoke Ophthalmology have also entered the marketing application stage, while Ocumension Therapeutics, Shapuaisi, and JMD Biomed are in late-stage clinical trials. Qilu Pharmaceutical stated that it is currently only an application, and the specific launch time is uncertain.
300573.CS ▲6622.HK ▼1477.HK ▼600276.CG ▼603168.CG ▼
Biotech & Genomic Medicine
红星资本局·30dRead more ▾
© 2026 MarketDXAsset